ArticleScientific reports2025
Urolithin A suppressed osteosarcoma cell migration and invasion via targeting MMPs and AKT1.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Coumarins in musculoskeletal health: a systematic review.Frontiers in nutrition · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is an aggressive malignancy marked by a high incidence of local recurrence and distant metastasis, leading to poor outcomes in advanced stages. While current therapies offer long-term survival primarily for patients with localized disease, effective treatments for metastatic cases remain elusive. Addressing this critical gap, the present study explores, for the first time, the anti-metastatic potential of urolithin A (UA), a naturally derived polyphenol, against osteosarcoma cells. Interactome mapping, gene enrichment profiling, target gene expression assessment, and molecular docking coupled with dynamics simulations were performed to elucidate the mechanistic basis of UA action. For experimental studies, UA was synthesized and its effects on osteosarcoma cell viability, apoptosis, migration, adhesion, invasion, and MMP activity were evaluated using alamarBlue assay, flow cytometry, scratch assay, fibronectin-based adhesion assay, Boyden chamber assay, and gelatin zymography, respectively. Results identified AKT1, EGFR, and MMP9 as potential targets of UA associated with osteosarcoma progression. Further analyses revealed critical interactions among these hub targets, with significant upregulation of AKT1 observed in osteosarcoma tissue samples. Molecular docking and dynamics simulations demonstrated strong and stable binding of UA to the kinase domain of AKT1 and the active site of EGFR. Experimental validation showed that treatment with UA significantly inhibited the migration and invasion of osteosarcoma cells, while notably enhancing cell adhesion. This anti-metastatic effect was closely linked to a marked reduction in enzymatic activity of MMP2 and MMP9, key mediators of metastatic dissemination. These findings position UA as a promising therapeutic candidate for targeting osteosarcoma metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.